Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2019 / Article
Special Issue

Oxidative Stress and Reprogramming of Mitochondrial Function and Dynamics as Targets to Modulate Cancer Cell Behavior and Chemoresistance

View this Special Issue

Research Article | Open Access

Volume 2019 |Article ID 8576961 | 10 pages | https://doi.org/10.1155/2019/8576961

Oleuropein-Induced Apoptosis Is Mediated by Mitochondrial Glyoxalase 2 in NSCLC A549 Cells: A Mechanistic Inside and a Possible Novel Nonenzymatic Role for an Ancient Enzyme

Academic Editor: Stefano Falone
Received09 Apr 2019
Revised06 Jun 2019
Accepted11 Jun 2019
Published22 Jul 2019


Oleuropein (OP) is a bioactive compound derived from plants of the genus Oleaceae exhibiting antitumor properties in several human cancers, including non-small-cell lung cancer (NSCLC). Recent evidence suggests that OP has proapoptotic effects on NSCLC cells via the mitochondrial apoptotic pathway. However, the exact molecular mechanisms behind the apoptogenic action of OP in NSCLC are still largely unknown. Glyoxalase 2 (Glo2) is an ancient enzyme belonging to the glyoxalase system involved in the detoxification of glycolysis-derived methylglyoxal. However, emerging evidence suggests that Glo2 may have also nonenzymatic roles in some malignant cells. In the present study, we evaluated whether and how Glo2 participated in the proapoptotic effects of OP in NSCLC A549 cells. Our results indicate that OP is able to induce apoptosis in A549 cells through the upregulation of mitochondrial Glo2 (mGlo2), mediated by the superoxide anion and Akt signaling pathway. Moreover, our data shows that the proapoptotic role of mGlo2, observed following OP exposure, occurs via the interaction of mGlo2 with the proapoptotic Bax protein. Conversely, OP does not alter the behavior of nonmalignant human BEAS-2B cells or mGlo2 expression, thus suggesting a specific anticancer role for this bioactive compound in NSCLC. Our data identify a novel pathway through which OP exerts a proapoptotic effect in NSCLC and suggest, for the first time, a novel, nonenzymatic antiapoptotic role for this ancient enzyme in NSCLC.

1. Introduction

1.1. OP and Cancer

Oleuropein (OP) is an olive-derived polyphenol with an array of pharmacological properties, including anti-inflammatory and antioxidant effects [1], which have fostered intense interest in cancer research as a putative anticancer agent. Specifically, several lines of in vitro [2, 3] and in vivo [1] evidence demonstrate both antiproliferative and proapoptotic effects of this secoiridoid.

1.2. Lung Cancer and OP Effect on Non-Small-Cell Lung Cancer (NSCLC)

Lung cancer is the leading worldwide cause of cancer mortality [4]. While recent years have seen notable advances in the treatment of many cancers, the prognosis for non-small-cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, remains dire. The lack of therapies capable of curing or even prolonging survival (estimated survival rate of only 15% at 5 years) of NSCLC highlights the urgent need for the identification of proteins and pathways responsible for the development and progression of the disease as potential drug targets for novel, effective, and safe therapeutic options. Epidemiologic studies have shown an inverse correlation between olive oil consumption and the risk of lung cancer [57], and recent findings have shown that OP exerts cytotoxic effects, by inducing mitochondrial apoptosis, in NSCLC cells [8, 9]. However, the molecular mechanisms driving the apoptogenic action of OP in NSCLC remain unclear.

1.3. Glyoxalases and Cancer

Glyoxalase 2 (Glo2) and glyoxalase 1 (Glo1) are together responsible for the detoxification of methylglyoxal (MG), a metabolic by-product of glycolysis with strongly proapoptotic effects [10]. Specifically, using glutathione (GSH) as a cofactor, Glo1 converts MG to S-D-lactoylglutathione (LSG) which is then hydrolyzed to D-lactate, regenerating GSH [10]. Recent evidence suggests that cancer cells show bioenergetic versatility depending on the genetic heterogeneity of the tumor [11, 12]. If on the one hand, many types of tumors consume larger amounts of glucose, compared to normal tissues, as Warburg originally observed, on the other hand, high glycolytic rates in tumors and mitochondrial respiration often operate simultaneously [11]. Moreover, it has been reported that cancer cells can also use a range of fuels including glutamine, fatty acids, heme flux, and acetate to sustain their growth and progression [11]. Cancers with enhanced glycolysis, such as prostate cancers [13, 14], are characterized by an increase in expression and enzyme activity of glyoxalases that reduce the production of MG, favoring escape from apoptosis [10, 15]. We have recently demonstrated, in prostate cancer cells, that Glo2 is involved in the control of apoptosis, in a Glo1-independent and possibly nonenzymatic manner, through the modulation of intracellular levels of p53 [16]. Here, we examined whether and how Glo2 might be involved in the proapoptotic effect of OP in NSCLC A549 cells and nonmalignant BEAS-2B cells.

2. Materials and Methods

2.1. Cells and Reagents

Human NSCLC A549 cells and human noncancerous BEAS-2B cells were purchased from Merck Spa (Milan, Italy). Cells were grown in RPMI-1640 (Thermo Fisher Scientific, Monza, Italy) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientific, Monza, Italy) and 1% antibiotics (penicillin-streptomycin) (Thermo Fisher Scientific, Monza, Italy) at 37°C in a humidified incubator with 5% CO2. Confluent cells were treated with OP (Vinci-Biochem Srl, Florence, Italy) at final concentrations of 50 and 150 μM (in dimethyl sulfoxide, DMSO) for 24 h [8, 9]. The most robust biological effects were obtained using 150 μM OP 24 h post exposure, so mechanistic studies were carried out using this concentration. Untreated cells, incubated for the same time period, were used as controls. Separately, the effects of joint treatment with the specific Akt inhibitor MK2206 (10 μM in DMSO for 48 hours) or SC79 Akt activator (4 μg/ml in DMSO for 30 minutes) followed by 150 μM OP for a further 24 hours were also examined. At the concentration, used MK2206 or SC79 exhibited no significant toxicity to cells. Unless otherwise stated, the biochemical evidence of inhibitor efficacy was established in preliminary experiments mainly by western blot analysis (data not shown). For agents in DMSO, final DMSO concentration in incubations was 0.01%. Controls contained an identical volume of DMSO vehicle. Laemmli buffer and the bicinchoninic acid (BCA) kit for protein quantification were from Thermo Fisher Scientific (Monza, Italy); Roti-Block was from Prodotti Gianni (Milan, Italy). The antibodies used in this study included the following: rabbit anti-Glo2 polyclonal antibody (pAb), mouse anti-Glo1 (D6) monoclonal antibody (mAb), mouse anti-rabbit anti-Bcl-XL pAb, rabbit anti-Bax (N20) pAb, rabbit anti caspase-3 pAb, and mouse anti-β-actin mAb from DBA Italia srl (Milan, Italy). Rabbit anti-p-Akt (Ser473) mAb was from Sigma-Aldrich (Milan, Italy); mouse anti-Bcl-2 mAb was from Dako (Milan, Italy); mouse anti-cytochrome c (Cyt c) mAb and mouse anti Apaf-1 mAb (clone 24) were from BD Pharmingen (Milan, Italy); mouse anti-Cyt c oxidase subunit IV (Cox IV) mAb was from Molecular Probes (Monza, Italy); mouse anti-SOD2 mAb was from Abcam (Milan, Italy).

2.2. Apoptosis Detection

Apoptosis was quantified by two methods, firstly by measuring the activation of caspase-3, using an enzyme-linked immunosorbent assay (ELISA) (Thermo Fisher Scientific, Monza, Italy), specific for activated human caspase-3 following the manufacturer’s instructions, and secondly by DNA fragmentation using agarose gel electrophoresis as previously described [17, 18].

2.3. Enzymatic Activity Assays

Enzymatic activity assays were conducted on cell extracts prepared as previously described [19]. Briefly, cells treated (24 h) with OP were harvested and resuspended (107 cells/ml) in 10 mM phosphate buffer pH 7.0, containing 1 mM dithiothreitol (for the detection of Glo2 and Glo1 enzymatic activities) and 0.1 mM phenylmethanesulphonylfluoride (PMSF). Cells were then homogenized with a Potter-Elvehjem homogenizer, and cell debris removed by centrifugation (13,000 x g for 30 min) and the resulting cell supernatants were assayed for protein content and enzymatic activity. Mitochondrial extracts were prepared using a Mitochondria/Cytosol Fractionation Kit (BioVision, Florence, Italy), according to the manufacturer’s instructions. Protein concentration was determined with a bicinchoninic acid (BCA) kit (Pierce), by reference to a standard curve prepared with bovine serum albumin. Glo1 activity was assayed according to Mannervik et al. [20]. The assay solution contained 0.1 M sodium-phosphate buffer pH 7.2, 2 mM MG, and 1 mM GSH. Activity was measured spectrophotometrically by monitoring the increase of absorbance at 240 nm at 25°C. One unit of activity was defined as 1 μmol of S-D-lactoylglutathione produced min-1. Conversely, Glo2 activity was assayed spectrophotometrically, at 25°C by recording the decrease in absorbance at 240 nm due to S-D-lactoylglutathione (0.3 mM) hydrolysis [21, 22]. One unit activity was defined as 1 μmol S-D-lactoylglutathione hydrolyzed/min. Finally, SOD activity was measured using Calbiochem’s Superoxide Dismutase Assay Kit II (EMD Chemicals, Gibbstown, NJ) according to the manufacturer’s directions. One unit of SOD activity was defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical.

2.4. Cell Lysate Preparation for Western Blot

Cells (106) were lysed in precooled radioimmunoprecipitation assay (RIPA) lysis buffer, proteins separated by SDS-PAGE, and subjected to Western blot analysis as previously described [23, 24]. Briefly, samples of equal protein concentration were mixed with Laemmli buffer and boiled for 5 minutes then resolved on 4-15% SDS-PAGE and blotted onto a nitrocellulose membrane (iBlot Dry Blotting System, Thermo Fisher Scientific, Monza, Italy). Membranes were blocked in Roti-Block for 1 h at room temperature, incubated overnight at 4°C with an appropriate dilution of the primary Abs. After washing with TBST, membranes were incubated (1 h, RT) with the appropriate HRP-conjugated secondary Ab and visualized using ECL (Amersham Pharmacia, Milan, Italy). The primary Ab was then stripped by incubating membranes in stripping buffer (100 mM 2-ME, 2% SDS, and 62.5 mM Tris-HCl, pH 6.8) and reprobed with an Ab against an appropriate housekeeping protein as an internal loading control.

2.5. Superoxide Anion Detection

Intracellular O2⋅- production after OP treatment was detected using dihydroethidium (DHE) (Sigma-Aldrich, Milan, Italy) [25, 26]. DHE enters cells and reacts with the superoxide anion to form ethidium, which exhibits red fluorescence. Briefly, confluent A549 cells were exposed to OP and then incubated with 5 μM DHE in HBSS (2 mM CaCl2, 1 mM MgSO4) at 37°C for 30 min. At the end of the incubation, cells were detached by scraping and disrupted by sonication. After clarification (13000 x g, 5 min, 4°C), supernatants were collected and fluorescence was measured using a fluorimeter (Kontrol Instrument, SFM 25, Eching, Germany) (excitation 488 nm, emission wavelength 512 nm). The results were confirmed using an HE-based HPLC assay (data not shown).

2.6. Gene Silencing

Pools of four small interfering RNA (siRNA) oligonucleotides targeting SOD2 (siSOD2) (ON-TARGET plus SMART pool siRNA) or non-targeting siRNA oligonucleotides (siCtr) (ONTARGET plus siCONTROL) as a negative control (all from Dharmacon RNA Technologies, Carlo Erba, Milan, Italy) were transiently transfected into NSCLC A549 cells using DharmaFECT 1 transfection reagent (Dharmacon RNA Technologies, Carlo Erba, Milan, Italy), according to the manufacturer’s instructions. Potential effects due solely to the transfection reagent were controlled by performing mock transfections without any siRNA (data not shown). Since the biological readouts examined here were indistinguishable in nontransfected, mock-treated, or siCtr-treated cells, the observed changes resulting from siSOD2 treatment were reported relative to siCtr-exposed cells only.

2.7. Immunoprecipitation

Immunoprecipitation (IP) was performed using Dynabeads Protein G Immunoprecipitation Kit (Thermo Fisher Scientific, Monza, Italy) according to the manufacturer’s instructions. Briefly, supernatants of cells lysed in ice-cold RIPA lysis buffer containing a protease inhibitor cocktail were incubated (4 h, 4°C) with protein G Dynabeads to which a rabbit anti-Glo2 Ab had been prebound (O/N, 4°C). Immune complexes were recovered magnetically and analyzed by Western blot using either anti-Bax or anti-Glo2 antibodies as described above.

2.8. Statistical Analysis

All data were generated from three independent biological replicates and expressed as the (SD). One-way analysis of variance with Dunnett’s correction was used to assess differences among groups when appropriate. The statistical significance, determined by Student’s -test, was set at .

3. Results and Discussion

3.1. The Proapoptotic Effect of OP Is Associated with Mitochondrial Glo2-Increased Expression in NSCLC A549 Cells

The proapoptotic effect of OP in NSCLC A549 cells and the related intrinsic apoptosis mechanism were evaluated by measuring the levels of major proteins typically activated in a mitochondrial apoptotic pathway, namely, the antiapoptotic Bcl-2 or Bcl-XL or the proapoptotic Bax proteins, Cyt c, Apaf-1, and the final executioner caspase-3 [18] by immunoblotting. As shown in Figure 1(a), we found a significant dose-dependent decrease in the levels of the antiapoptotic Bcl-2 or Bcl-XL proteins paralleled by a marked increase in the levels of the proapoptotic Bax protein as well as its translocation from the cytosol to the mitochondria, in OP-exposed cells compared to controls. Concomitantly, Cyt c release into the cytosol, as well as the activation of Apaf-1 and caspase-3, was observed (Figure 1(a)). DNA fragmentation into oligonucleosomes, a hallmark of apoptosis, confirmed the apoptotic responses at the morphological level, as evidenced by the typical DNA laddering response (Figure 1(b)). Hence, in line with the literature [8, 9], our results show that OP induces apoptosis in NSCLC A549 cells through a mitochondrial pathway. Glo2 is an ancient enzyme that together with Glo1 participates in the removal of cytotoxic MG [10]. Very little is known about Glo2, including its role in MG scavenging and its functional significance in health and disease [10, 15, 16]. We have recently demonstrated, in prostate cancer cells, that Glo2 is involved in the control of apoptosis, in a Glo1-independent and possibly nonenzymatic manner, through the modulation of intracellular levels of p53 [16]. In particular, Glo2 protected cancer cells from apoptosis [16]. In humans, two Glo2 isoforms have been identified, one in the cytosol (cGlo2) and one in the mitochondrion (mGlo2) [27]. These isoforms are encoded by a single Glo2 gene through alternate translational start sites [28]. In order to investigate whether Glo2 could be involved in OP-induced apoptosis, we studied the protein expression and specific activity of the Glo2 enzyme in the mitochondrial and cytosolic fractions of A549 cells exposed to OP. Unexpectedly, we found that OP induced a dose-dependent and statistically significant increase in mGlo2 protein levels without affecting the enzyme’s specific activity (Figure 1(c)). Similarly, OP did not modify cGlo2 expression either at protein or at functional level (Figure 1(d)). Overall, these results indicated that the proapoptotic effect of OP is associated with an increase in mGlo2, suggesting a novel mechanism by which this natural bioactive compound exerts its apoptogenic function in NSCLC A549. Moreover, our findings suggest a proapoptotic role of Glo2, at least of the mitochondrial isoform and at least following OP exposure in NSCLC A549 cells. This role turns out to be opposite to that observed for Glo2 in prostate cancer cells, where conversely, an antiapoptotic nonenzymatic role of this protein was described [10]. Even though the antiapoptotic action of Glo2 in prostate cancer cells has been shown without discriminating between the mitochondrial or cytosolic isoform, our findings highlight a potential and intriguing complexity of Glo2 biology, providing powerful motivation for further research. Moreover, these data showed that mGlo2 involvement in the apoptosis driven by OP is independent from its traditional function as a metabolic enzyme, positing this isoform as a “moonlighting” protein (a protein with more than one function), as has been documented for other “ancient” metabolic enzymes [29, 30], and in agreement with the emerging role for Glo2 in other malignant cells [16].

3.2. OP Induces Apoptosis through a Mechanism Involving SOD2-Mediated Superoxide Anion-Dependent mGlo2 Upregulation in NSCLC A549 Cells

It has been shown that OP exerts antioxidant effects either directly by reducing the generation of reactive oxygen species (ROS) or indirectly through modulating endogenous antioxidant enzymes [31, 32]. In particular, it has been reported that OP has a potent superoxide anion scavenging activity [32]. In addition, because the mitochondria are the major sources of ROS production, mGlo2 may be somehow affected by the redox status of these organelles. Finally, it is known that Mn-superoxide dismutase (SOD2) plays a crucial role in the control of the mitochondrial apoptotic pathway [33]. Hence, we investigated whether OP-induced apoptosis occurred through the SOD2-mediated depletion of the superoxide anion (O2⋅-). As shown in Figure 2, OP induced a significant increase in SOD2 activity compared with untreated cells (Figure 2(a)) and this was paralleled by a marked decrease in O2⋅- levels (Figure 2(b)). More importantly, striking SOD2 silencing, demonstrable by measurements of both protein expression and levels of enzyme activity (Figure 2(c)), was able, following 150 μM OP exposure, to restore normal O2⋅- levels (Figure 2(d)) and to decrease mGlo2 expression (Figure 2(e)) and apoptosis (Figure 2(f)).

Collectively, our results define a novel mechanism, based on the involvement of SOD2, O2⋅-, and mGlo2 in the proapoptotic effect of OP, thus adding further insight into the molecules activated by this bioactive compound in inducing apoptosis. The issue of whether the action of OP on malignant cells is predominantly antioxidant or prooxidant remains to be established. While in many cases, the proapoptotic effects of OP on tumor cells are elicited via pathways involving ROS generation and oxidative stress [34, 35], in others, OP has been reported to mediate antioxidant effects. Our results are in agreement with the studies supporting this last assessment [36, 37]. Moreover, our data suggest a role for mGlo2 in the group of the proteins participating in ROS-mediated apoptosis, thus providing further insight to the mechanisms underlying ROS-dependent apoptosis, which are still far from being completely understood [38].

3.3. OP Drives Apoptosis in NSCLC A549 Cells by Promoting mGlo2 Association to Bax

To begin to address the mechanism by which mGlo2 could promote apoptosis after OP exposure, we decided to address whether mGlo2 could interact with proteins involved in the known mitochondrial apoptosis pathway. We found that OP promoted mGlo2 association with the proapoptotic Bax protein (Figure 3(a)) and this was partially reversed by SOD2 silencing (Figure 3(b)).

Thus, our data provide evidence of a proapoptotic role for mGlo2 after OP exposure as well as a physical association with a known mediator of apoptosis, Bax. It has been demonstrated that during apoptosis, Bax and Bak mediate the release of cytochrome c from the mitochondria by clustering on the outer mitochondrial membrane and thereby increasing its permeability [39]. However, it remains unclear how outer membrane openings form. Based on our data, we hypothesize that Glo2 might help in achieving this goal, a possibility which needs further investigation. Our data on the interaction between Glo2 and Bax, although novel, are in fact in agreement with the proposal that Glo2 might form specific protein-protein interactions with its enzyme substrates as reported by Ercolani et al. [40]. Glyoxalases are ubiquitous enzymes. In yeast, it has been reported that the mGlo2 complements the cytosolic form in the detoxification of MG [28]. The role of mGlo2 in humans has been less investigated, and in agreement with our results, it does not appear to have an MG-scavenging function [16]. Recently, Navarro et al. have described an antiglycative role of OP in the HepG2 cell line [41]. In particular, they found that OP was able to trap MG, the cytotoxic metabolite preferentially detoxified by cGlo2 in cooperation with Glo1. We speculate that cGlo2 might not participate in the apoptotic effects of OP since OP directly reduces levels of MG.

3.4. OP-Induced mGlo2 Upregulation Is Dependent on p38 MAPK and Akt Signaling Pathways

One of the most frequent events in carcinogenesis is the hyperactivation of the Akt signaling pathway [42, 43]. In NSCLC, activation of the Akt pathway promotes tumor progression by inducing evasion of apoptosis [44]. Here, we wanted to investigate whether the OP-induced increase in mGlo2 expression was paralleled by Akt desensitization and apoptosis induction. We first showed that Akt signaling is active in basal A549 cells and that OP reduced its activation (Figure 4(a)). Subsequently, by using the selective MK2206 (MK) Akt inhibitor, we demonstrated that OP-induced mGlo2 expression was upregulated by Akt deactivation and this was associated with a reversal of apoptosis. In fact, following OP administration, MK treatment potentiated mGlo2 protein expression (Figure 4(b)) and apoptosis (Figure 4(c)). Akt activation by SC79 [45] further confirmed that OP-induced mGlo2 upregulation is Akt-dependent (Figures 4(d) and 4(e)). The control of mGlo2 expression by Akt deactivation in our model is further supported by our observation that O2⋅- depletion mediated an additional increase in the mGlo2 protein level after OP exposure. In fact, it was previously reported that O2⋅- sustains A549 cell survival by supporting Akt activation [46]. Hence, it is plausible to assume that OP-induced depletion of O2⋅- in our model leads to Akt deactivation and, in turn, to the upregulation of mGlo2.

3.5. OP Effect on the Viability and Glyoxalase Expression in Nonmalignant BEAS-2B Cells

Most conventional anticancer therapies do not categorize between cancerous and normal cells, leading to unwanted side effects and toxicity. In agreement with the literature [8], we found here that OP did not affect the viability of normal BEAS-2B cells (data not shown). Moreover, no apoptosis was observed after OP exposure (Figure 5(a)), thus suggesting a selective toxicity against A549 cancer cells while sparing healthy, nonmalignant cells. Moreover, in BEAS-2B cells, OP did not affect mGlo2 expression or enzyme activity (Figure 5(b)), thus suggesting that the viability of BEAS-2B cells and malignant A549 cells is regulated by different proteins and mechanisms. Intriguingly, OP increased the protein expression and enzyme activity of both the cytosolic Glo2 isoform (Figure 5(c)) and Glo1 (Figure 5(d)), which needs further investigation.

4. Conclusions

The data reported here show that OP induces apoptosis in NSCLC A549 cells through a novel mechanism involving the SOD2/O2⋅-/Akt/mGlo2 axis (Figure 6), thus identifying mGlo2 as a crucial protein in OP-driven apoptosis and extending the limited information available on the anticancer effect of OP in NSCLC models [8, 9]. In addition, our results further supporting the idea that the pro-apoptotic role of OP in NSCLC cells, together with the absence of toxic effects on healthy cells, make this bioactive natural compound an excellent candidate for treating this malignancy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.


This work was supported by grants from Italian Ministry of Education, University and Research (MIUR), and from the Università degli Studi di Perugia (local research grants 2014 to CA). MFS was supported by the Fondazione Umberto Veronesi (Post-Doctoral Fellowship 2019).


  1. B. Barbaro, G. Toietta, R. Maggio et al., “Effects of the olive-derived polyphenol oleuropein on human health,” International Journal of Molecular Sciences, vol. 15, no. 10, pp. 18508–18524, 2014. View at: Publisher Site | Google Scholar
  2. I. Casaburi, F. Puoci, A. Chimento et al., “Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies,” Molecular Nutrition & Food Research, vol. 57, no. 1, pp. 71–83, 2013. View at: Publisher Site | Google Scholar
  3. S. Bayat, S. Mansoori Derakhshan, N. Mansoori Derakhshan, M. Shekari Khaniani, and M. R. Alivand, “Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF‐7 breast cancer cells,” Journal of Cellular Biochemistry, vol. 120, no. 6, pp. 9172–9180, 2019. View at: Publisher Site | Google Scholar
  4. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at: Publisher Site | Google Scholar
  5. C. Fortes, F. Forastiere, S. Farchi et al., “The protective effect of the Mediterranean diet on lung cancer,” Nutrition and Cancer, vol. 46, no. 1, pp. 30–37, 2003. View at: Publisher Site | Google Scholar
  6. J. J. Johnson, “Carnosol: a promising anti-cancer and anti-inflammatory agent,” Cancer Letters, vol. 305, no. 1, pp. 1–7, 2011. View at: Publisher Site | Google Scholar
  7. T. J. Smith, “Squalene: potential chemopreventive agent,” Expert Opinion on Investigational Drugs, vol. 9, no. 8, pp. 1841–1848, 2000. View at: Publisher Site | Google Scholar
  8. S. Cao, X. Zhu, and L. Du, “P38 MAP kinase is involved in oleuropein-induced apoptosis in A549 cells by a mitochondrial apoptotic cascade,” Biomedicine & Pharmacotherapy, vol. 95, pp. 1425–1435, 2017. View at: Publisher Site | Google Scholar
  9. W. Wang, J. Wu, Q. Zhang et al., “Mitochondria-mediated apoptosis was induced by oleuropein in H1299 cells involving activation of p38 MAP kinase,” Journal of Cellular Biochemistry, vol. 120, no. 4, pp. 5480–5494, 2019. View at: Publisher Site | Google Scholar
  10. C. Antognelli and V. N. Talesa, “Glyoxalases in urological malignancies,” International Journal of Molecular Sciences, vol. 19, no. 2, p. 415, 2018. View at: Publisher Site | Google Scholar
  11. M. M. Alam, S. Lal, K. E. FitzGerald, and L. Zhang, “A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors,” Clinical and Translational Medicine, vol. 5, no. 1, p. 3, 2016. View at: Publisher Site | Google Scholar
  12. P. Danhier, P. Bański, V. L. Payen et al., “Cancer metabolism in space and time: beyond the Warburg effect,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol. 1858, no. 8, pp. 556–572, 2017. View at: Publisher Site | Google Scholar
  13. J. Liu, G. Chen, Z. Liu et al., “Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer,” Cancer Research, vol. 78, no. 16, pp. 4459–4470, 2018. View at: Publisher Site | Google Scholar
  14. C. Wang, W. Tao, S. Ni, and Q. Chen, “SENP1 interacts with HIF1α to regulate glycolysis of prostatic carcinoma cells,” International Journal of Biological Sciences, vol. 15, no. 2, pp. 395–403, 2019. View at: Publisher Site | Google Scholar
  15. V. N. Talesa, I. Ferri, G. Bellezza, H. D. Love, A. Sidoni, and C. Antognelli, “Glyoxalase 2 is involved in human prostate cancer progression as part of a mechanism driven by PTEN/PI3K/AKT/mTOR signaling with involvement of PKM2 and ERα,” Prostate, vol. 77, no. 2, pp. 196–210, 2017. View at: Publisher Site | Google Scholar
  16. C. Antognelli, I. Ferri, G. Bellezza et al., “Glyoxalase 2 drives tumorigenesis in human prostate cells in a mechanism involving androgen receptor and p53-p21 axis,” Molecular Carcinogenesis, vol. 56, no. 9, pp. 2112–2126, 2017. View at: Publisher Site | Google Scholar
  17. C. Antognelli, F. Mancuso, R. Frosini et al., “Testosterone and follicle stimulating hormone-dependent glyoxalase 1 up-regulation sustains the viability of porcine Sertoli cells through the control of hydroimidazolone- and argpyrimidine-mediated NF-κB pathway,” American Journal of Pathology, vol. 188, no. 11, pp. 2553–2563, 2018. View at: Publisher Site | Google Scholar
  18. C. Antognelli, A. Gambelunghe, G. Muzi, and V. N. Talesa, “Peroxynitrite-mediated glyoxalase I epigenetic inhibition drives apoptosis in airway epithelial cells exposed to crystalline silica via a novel mechanism involving argpyrimidine-modified Hsp70, JNK, and NF-κB,” Free Radical Biology & Medicine, vol. 84, pp. 128–141, 2015. View at: Publisher Site | Google Scholar
  19. C. Antognelli, A. Gambelunghe, G. Muzi, and V. N. Talesa, “Glyoxalase I drives epithelial-to-mesenchymal transition via argpyrimidine-modified Hsp70, miR-21 and SMAD signalling in human bronchial cells BEAS-2B chronically exposed to crystalline silica Min-U-Sil 5: transformation into a neoplastic-like phenotype,” Free Radical Biology & Medicine, vol. 92, pp. 110–125, 2016. View at: Publisher Site | Google Scholar
  20. B. Mannervik, A.-C. Aronsson, E. Marmstal, and G. Tibellin, “Glyoxalase I (rat liver),” Methods Enzymology, vol. 77, pp. 297–301, 1981. View at: Publisher Site | Google Scholar
  21. M. K. Guha, D. L. Vander Jagt, and D. J. Creighton, “Diffusion-dependent rates for the hydrolysis reaction catalyzed by glyoxalase II from rat erythrocytes,” Biochemistry, vol. 27, no. 24, pp. 8818–8822, 1988. View at: Publisher Site | Google Scholar
  22. S. Falone, S. J. Santini, V. Cordone et al., “Regular and moderate exercise counteracts the decline of antioxidant protection but not methylglyoxal-dependent glycative burden in the ovary of reproductively aging mice,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3837623, 13 pages, 2016. View at: Publisher Site | Google Scholar
  23. C. Antognelli, E. Trapani, S. Delle Monache et al., “KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress: implication for cerebral cavernous malformation disease,” Free Radical Biology & Medicine, vol. 115, pp. 202–218, 2018. View at: Publisher Site | Google Scholar
  24. L. Marinucci, S. Balloni, K. Fettucciari, M. Bodo, V. N. Talesa, and C. Antognelli, “Nicotine induces apoptosis in human osteoblasts via a novel mechanism driven by H2O2 and entailing Glyoxalase 1-dependent MG-H1 accumulation leading to TG2-mediated NF-kB desensitization: implication for smokers-related osteoporosis,” Free Radical Biology and Medicine, vol. 117, pp. 6–17, 2018. View at: Publisher Site | Google Scholar
  25. I. Passagne, M. Morille, M. Rousset, I. Pujalté, and B. L’Azou, “Implication of oxidative stress in size-dependent toxicity of silica nanoparticles in kidney cells,” Toxicology, vol. 299, no. 2-3, pp. 112–124, 2012. View at: Publisher Site | Google Scholar
  26. C. Antognelli, A. Gambelunghe, V. N. Talesa, and G. Muzi, “Reactive oxygen species induce apoptosis in bronchial epithelial BEAS-2B cells by inhibiting the antiglycation glyoxalase I defence: involvement of superoxide anion, hydrogen peroxide and NF-κB,” Apoptosis, vol. 19, no. 1, pp. 102–116, 2014. View at: Publisher Site | Google Scholar
  27. A. Bito, M. Haider, P. Briza, P. Strasser, and M. Breitenbach, “Heterologous expression, purification, and kinetic comparison of the cytoplasmic and mitochondrial glyoxalase II enzymes, Glo2p and Glo4p, from Saccharomyces cerevisiae,” Protein Expression and Purification, vol. 17, no. 3, pp. 456–464, 1999. View at: Publisher Site | Google Scholar
  28. P. A. Cordell, T. S. Futers, P. J. Grant, and R. J. Pease, “The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II,” Journal of Biological Chemistry, vol. 279, no. 27, pp. 28653–28661, 2004. View at: Publisher Site | Google Scholar
  29. L. Zheng, R. G. Roeder, and Y. Luo, “S-phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component,” Cell, vol. 114, no. 2, pp. 255–266, 2003. View at: Publisher Site | Google Scholar
  30. E. N. Kozhevnikova, J. A. van der Knaap, A. V. Pindyurin et al., “Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state,” Molecular Cell, vol. 47, no. 1, pp. 133–139, 2012. View at: Publisher Site | Google Scholar
  31. P. G. Lins, S. Marina Piccoli Pugine, A. M. Scatolini, and M. P. de Melo, “In vitro antioxidant activity of olive leaf extract (Olea europaea L.) and its protective effect on oxidative damage in human erythrocytes,” Heliyon, vol. 4, no. 9, article e00805, 2018. View at: Publisher Site | Google Scholar
  32. X. Bi, W. Li, T. Sasaki et al., “Secoiridoid glucosides and related compounds from Syringa reticulata and their antioxidant activities,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 21, pp. 6426–6429, 2011. View at: Publisher Site | Google Scholar
  33. N. S. Chandel and G. R. S. Budinger, “The cellular basis for diverse responses to oxygen,” Free Radical Biology & Medicine, vol. 42, no. 2, pp. 165–174, 2007. View at: Publisher Site | Google Scholar
  34. C. M. Yan, E. Q. Chai, H. Y. Cai, G. Y. Miao, and W. Ma, “Oleuropein induces apoptosis via activation of caspases and suppression of phosphatidylinositol 3-kinase/protein kinase B pathway in HepG2 human hepatoma cell line,” Molecular Medicine Reports, vol. 11, no. 6, pp. 4617–4624, 2015. View at: Publisher Site | Google Scholar
  35. J. S. Cheng, C. T. Chou, Y. Y. Liu et al., “The effect of oleuropein from olive leaf (Olea europaea) extract on Ca2+ homeostasis, cytotoxicity, cell cycle distribution and ROS signaling in HepG2 human hepatoma cells,” Food and Chemical Toxicology, vol. 91, pp. 151–166, 2016. View at: Publisher Site | Google Scholar
  36. S. Bulotta, R. Corradino, M. Celano et al., “Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells,” Journal of Molecular Endocrinology, vol. 51, no. 1, pp. 181–189, 2013. View at: Publisher Site | Google Scholar
  37. C. Shi, X. Chen, Z. Liu et al., “Oleuropein protects L-02 cells against H2O2-induced oxidative stress by increasing SOD1, GPx1 and CAT expression,” Biomedicine & Pharmacotherapy, vol. 85, pp. 740–748, 2017. View at: Publisher Site | Google Scholar
  38. K. Abbas, M. Hardy, F. Poulhès et al., “Detection of superoxide production in stimulated and unstimulated living cells using new cyclic nitrone spin traps,” Free Radical Biology & Medicine, vol. 71, pp. 281–290, 2014. View at: Publisher Site | Google Scholar
  39. S. Bleicken, T. E. Assafa, C. Stegmueller, A. Wittig, A. J. Garcia-Saez, and E. Bordignon, “Topology of active, membrane-embedded Bax in the context of a toroidal pore,” Cell Death and Differentiation, vol. 25, no. 10, pp. 1717–1731, 2018. View at: Publisher Site | Google Scholar
  40. L. Ercolani, A. Scirè, R. Galeazzi et al., “A possible S-glutathionylation of specific proteins by glyoxalase II: an in vitro and in silico study,” Cell Biochemistry and Function, vol. 34, no. 8, pp. 620–627, 2016. View at: Publisher Site | Google Scholar
  41. M. Navarro, F. J. Morales, and S. Ramos, “Olive leaf extract concentrated in hydroxytyrosol attenuates protein carbonylation and the formation of advanced glycation end products in a hepatic cell line (HepG2),” Food & Function, vol. 8, no. 3, pp. 944–953, 2017. View at: Publisher Site | Google Scholar
  42. E. Perumal, K. So Youn, S. Sun et al., “PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of β-catenin and snail/slug in non-small cell lung carcinoma cells,” Lung Cancer, vol. 130, pp. 25–34, 2019. View at: Publisher Site | Google Scholar
  43. W. L. Zhang, Y. N. Zhao, Z. Z. Shi, D. Cong, and Y. S. Bai, “Lutein inhibits cell growth and activates apoptosis via the PI3K/AKT/mTOR signaling pathway in A549 human non-small-cell lung cancer cells,” Journal of Environmental Pathology, Toxicology and Oncology, vol. 37, no. 4, pp. 341–350, 2018. View at: Publisher Site | Google Scholar
  44. U. Baumgartner, F. Berger, A. Hashemi Gheinani, S. S. Burgener, K. Monastyrskaya, and E. Vassella, “miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer,” Molecular Cancer, vol. 17, no. 1, p. 44, 2018. View at: Publisher Site | Google Scholar
  45. H. Jo, S. Mondal, D. Tan et al., “Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 26, pp. 10581–10586, 2012. View at: Publisher Site | Google Scholar
  46. Y. Liu, Q. F. Shi, Y. C. Ye, S. I. Tashiro, S. Onodera, and T. Ikejima, “Activated O2•− and H2O2 Mediated Cell Survival in SU11274-Treated Non-Small-Cell Lung Cancer A549 Cells via c-Met–PI3K–Akt and c-Met–Grb2/SOS–Ras–p38 Pathways,” Journal of Pharmacological Sciences, vol. 119, no. 2, pp. 150–159, 2012. View at: Publisher Site | Google Scholar

Copyright © 2019 Cinzia Antognelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

678 Views | 250 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.